Option chain shows key data for Orexo's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Orexo.

Orexo (OTC:ORXOF) Stock, Option Chain

Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.

Biotech

News

Penny Stocks

Health Care

General

INVVY

IZQVF

ORXOF

ORXOY

The FDA warned patients and prescribers about the risk of potential dental problems arising from the us

Using Opioid Addiction Drug Buprenorphine May Cause Dental Issues, FDA Flags

Guidance

Contracts

Management

Global

FDA Approves Zubsolv for Maintenance Treatment of Opioid Dependence 

Orexo AB

The&nbsp;<a class="editor-rtfLink" href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-risks-dental-problems-associated-buprenorphine-medicines-dissolved-mouth-treat" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">FDA warned patients and prescribers</a>&nbsp;about the risk of potential dental problems arising from the use of buprenorphine medicines to treat opioid addiction and pain.
<ul>
<li>The agency said the opioid addiction treatment had been reported to cause tooth decay, infection, and, in some cases, total tooth loss in patients with no history of dental issues.</li>
<li>The buprenorphine medicines that are associated with dental problems are tablets dissolved under the tongue and films placed against the inside of the cheek.</li>
<li>The FDA approved buprenorphine as a tablet in 2002 and as a film in 2015.</li>
<li>It said patients might lessen their risk by taking preventative measures.</li>
<li>After the product is completely dissolved, patients should take a large sip of water, swish it gently around their teeth and gums, and swallow, waiting for at least one hour before brushing their teeth after using the product to avoid damage to the teeth.</li>
<li>The regulator&#39;s approved buprenorphine products include&nbsp;Orexo AB&#39;s&nbsp;(OTC:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/orxof#OTC" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">ORXOF</a>) Zubsolv and&nbsp;Indivior Plc&#39;s&nbsp;(OTC:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/invvy#OTC" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">INVVY</a>) Suboclade.</li>
</ul>

Orexo U.S (OTC: <a class="ticker" href="/stock/orxof#OTC">ORXOF</a>) announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Zubsolv (buprenorphine and naloxone) sublingual tablets (CIII).&nbsp;Zubsolv is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and&hellip;Orexo U.S (OTC: <a class="ticker" href="/stock/orxof#OTC">ORXOF</a>) announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Zubsolv (buprenorphine and naloxone) sublingual tablets (CIII).&nbsp;Zubsolv is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Zubsolv is a once-daily, sublingual tablet with higher bioavailability, a fast dissolve time, smaller tablet size and a new menthol flavor.
Opioid dependence is a disease, like hypertension, schizophrenia or diabetes, and affects nearly 5 million people across the United States.i,ii,iii Although it is a treatable condition, about 60 percent of opioid dependent patients in the U.S. do not receive treatment.iii Every year thousands of patients continue to misuse opioids rather than risk public exposure by receiving treatment.iv
 <a href="http://www.benzinga.com/pressreleases/13/07/n3730901/u-s-fda-approves-zubsolv-for-the-maintenance-treatment-of-opioid-depend">See full press release</a>

Orexo AB reports Q3 results

Press Releases

Orexo publishes the Annual and Sustainability Report for 2023

Orexo announces that the condition for early redemption of its existing bonds has been fulfilled

Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US

Report from Orexo AB's annual general meeting, 26 April 2024

Earnings

Orexo Q1 2024 Interim Report

Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm

Orexo: invitation to presentation of the Q2 2024 Interim Report

Small Cap

Orexo AB's sustainability work ranked among top 5% by EcoVadis

Orexo Q2 2024 Interim Report

Orexo to participate in Pareto Securities' 15th Annual Healthcare Conference 2024

Orexo

Comments

Orexo

Orexo (ORXOF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga